Synthetic neomycin-kanamycin phosphotransferase, type II coding sequence for gene targeting in mammalian cells.
The bacterial neomycin-kanamycin phosphotransferase, type II enzyme is encoded by the neo gene and confers resistance to aminoglycoside drugs such as neomycin and kanamycin-bacterial selection and G418-eukaryotic cell selection. Although widely used in gene targeting in mouse embryonic stem cells, the neo coding sequence contains numerous cryptic splice sites and has a high CpG content. At least the former can cause unwanted effects in cis at the targeted locus. We describe a synthetic sequence, sneo, which encodes the same protein as that encoded by neo. This synthetic sequence has no predicted splice sites in either strand, low CpG content, and increased mammalian codon usage. In mouse embryonic stem cells sneo expressability is similar to neo. The use of sneo in gene targeting experiments should substantially reduce the probability of unwanted effects in cis due to splicing, and perhaps CpG methylation, within the coding sequence of the selectable marker.
Jin
Seung-Gi
SG
Division of Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Mann
Jeffrey R
JR
D000818:Animals; D003062:Codon / Q000235:genetics; D018899:CpG Islands / Q000235:genetics; D019175:DNA Methylation; D004351:Drug Resistance; D018390:Gene Targeting / Q000379:methods*; D007612:Kanamycin / Q000378:metabolism* / Q000494:pharmacology; D051379:Mice; D009355:Neomycin / Q000378:metabolism* / Q000494:pharmacology; D010770:Phosphotransferases / Q000145:classification / Q000235:genetics* / Q000378:metabolism*; D022821:RNA Splice Sites / Q000235:genetics; D013234:Stem Cells / Q000187:drug effects / Q000378:metabolism
D003062:Codon; D022821:RNA Splice Sites; D007612:Kanamycin; D010770:Phosphotransferases; D009355:Neomycin